spero therapeutics inc investor relations

Thanks for the question. Hourly rate can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have spent in your profession. And to your point, absolutely fatigue will be an important domain that will be assessed in the studies. CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a multi-asset clinical-stage biopharmaceutical Such forward-looking statements are not a guarantee of performance, and the companys actual results could differ materially from those contained in such statements. What does an Investor Relations Manager do at companies like SPERO THERAPEUTICS INC? We believe pairing a positive result on this primary endpoint with supportive evidence and learning from the trial secondary endpoints will enable us to substantially de-risk the program and move confidently to late-stage development. 2022 Spero Therapeutics. Learn More Recently Published PASTEUR Act Reintroduced Pipeline Explore Spero's Pipeline Oops! One is that, ARIKAYCE is a different drug. For more information about partnership opportunities, contact us. Exciting. Details are as follows: Cowen 43rd Annual Healthcare ConferenceInfectious Disease Corporate Panel: Tuesday, March 7, 2023, from 9:10 AM-10:10 AM ETWebcast Link: https://wsw.com/webcast/cowen132/panel3/2242422, Oppenheimer 33rd Annual Healthcare Conference Corporate Presentation: Tuesday, March 14, 2023, from 4:00 PM-4:30 PM ETWebcast Link: https://wsw.com/webcast/oppenheimer27/spro/2828084. (Copyright 2023 Salary.com). Im pleased to report that the program continues to advance according to plan. Salary.com's CompAnalyst platform offers: These charts show the average base salary (core compensation), as well as the average total cash compensation for Investor Relations Manager in companies like SPERO THERAPEUTICS INC in the United States. Typically requires a bachelor's degree. The two parties have also entered into a licensing agreement for SPR206, Speros intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting. Additionally, Spero has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting. By creating this job alert, you agree to the LinkedIn User Agreement and Privacy Policy. Investor Relations Contact: So as we get into the SPA process and then expect to report that out in the middle of the year along with details on the trial design, well be able to give you much greater clarity on the milestones from GSK. Please go ahead. For further details on our financials, please refer to our 10-Q filed with the SEC today. These forward-looking statements speak only as of the date of this conference call, and the company undertakes no obligation to publicly update any forward-looking statements or supply new information regarding the company after the date of todays call. CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases today announced that Pfizer Inc. (NYSE: PFE) has made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. June 17, 2021. Challenging. You may disconnect your lines. Unleashing the next wave of scientific innovations, Research and Business Development Partnerships, Sign up for the latest Pfizer Wire news alerts. Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. In exchange for these rights, Spero is eligible to receive up to $80 million in development and sales milestones, and high single digit to low double-digit royalties on net sales of SPR206 in these territories. Stimulating. Spero Therapeutics was founded in 2013. Our world-class team of biotechnology and biopharmaceutical experts embraces the Italian word spero which means hope. It is our mission to bring hope to patients and families of loved ones suffering from serious infections. [Operator Instructions] Please be advised that this call is being recorded, and replay will be available. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases.Speros lead product candidate is SPR720, a novel oral therapy for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. Stock information, SEC filings, corporate governance, IR resources and more. This compares to loss of $0.63 per share a year ago. The base salary for Investor Relations Manager in companies like SPERO THERAPEUTICS INC range from $123,587 to $174,438 with the average base salary of $153,699. Head onto Storrow Drive and continue onto Soldiers Field Road. Referrals increase your chances of interviewing at Avidity Biosciences, Inc. by 2x. WebSPR720. Long Beach, CA. Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance IR@sperotherapeutics.com (617) 798-4039. The archived webcast will also be available on Spero's website for 30 days following the call. WebJob Title: Director, Investor Relations . Your submission has been received! Committed. Please go ahead. Nontuberculous Mycobacteria (NTM) Infections. Committed. Clackamas, OR, Compassion & Choices - Investor Relations Intelligence; Featured Solutions The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved. Committed. When expanded it provides a list of search options that will switch the search inputs to match the current selection. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline. WebExcitement about the vision and mission of Sage. To conclude my section of todays call, Ill very briefly touch on SPR206, which is an investigational next generation polymyxin antibiotic being developed to treat multi-drug resistant gram-negative infections. LifeSci Advisors[emailprotected] So if you were to assume that we expect to get milestones to jumpstart the trial and those will be more than sufficient to initiate the trial on its rollout. And certainly if you know, and as and when we think about the U.S. rights for 206, well explore that more. And finally, as we think about the pathophysiology of the disease, if were trying to measure, feel and function type of endpoints, its physiologically more relevant for patients who can recover that lung function relative to those who have chronic inflammatory lung damage. We look forward to continuing that partnership. And so it sort of puts into frame some additional validation that the measures were looking at are going to be relevant as we build them into a PRO. WebThese forward-looking statements should not be relied upon as representing Spero s views as of any date subsequent to the date of this press release. Speros lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Thanks, Ritu, for the question. Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. Investor Relations Manager in Atlantic City, NJ. NY. Investor Relations Contact:Ted JenkinsVice President, Investor Relations and Strategic FinanceIR@sperotherapeutics.com (617) 798-4039, Media Inquiries:Lora Grassilli, Health Media RelationsZeno Grouplora.grassilli@zenogroup.com646-932-3735. With the business potentially at an important milestone, we thought we'd take a closer look at Spero Therapeutics, Inc.'s (NASDAQ:SPRO) future prospects. Thanks for taking all the questions. Is this happening to you frequently? SPERO THERAPEUTICS INC Investor Relations Administrator, Investor Relations Administrator Salaries with a Bachelor's Degree, Investor Relations Administrator Salaries with a Master's Degree or MBA, Investor Relations Administrator Salaries with a JD, MD, PhD or Equivalent, Detailed skills and competency reports for specific positions. Great. Please disable your ad-blocker and refresh. Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing Corte Madera, CA, JetZero, Inc. - Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether tebipenem HBr will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from theFDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; the lengthy, expensive, and uncertain process of clinical drug development for SPR720 and SPR206; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero's reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; whether Speros cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the Risk Factors set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. Thank you! They were running a trial looking at generic standard of care agents, and that was nice data for us to validate that some of the measures were looking at can be relevant in that three month or later timeframe. Explore Investor Resources Careers Collaborative. Published Sep 27, 2021 2:44PM EDT Every investor in Spero Therapeutics, Inc. (NASDAQ:SPRO) should be aware of the most powerful shareholder groups. You can save your resume and apply to jobs in minutes on LinkedIn, Marketing, Public Relations, and Writing/Editing, Research Services, Biotechnology Research, and Pharmaceutical Manufacturing, Communications & Media Relations Coordinator, Specialist, Global Corporate Communications, Public Relations and Communications Assistant - Entry Level, Manager, Corporate Affairs & Communications, North America, Public Relations Communications Assistant, See who Avidity Biosciences, Inc. has hired for this role, Team Scheduling including investor and analyst meetings, Managing conference and NDR logistics including tracking, monitoring schedules, registrations, calendar scheduling, and partnering/coordination with the administrative team, Coordinating Investor and Analyst volume series logistics, Press Release PRN and Nasdaq disclosure submissions, Monitoring and updates to Comms plans as required & ensuring timelines are executed, Familiarity with social media, including calendar tracking and approvals, Managing and tracking Communications and Investor Relations contracts, Assist with internal communications, intranet updates as directed, Management of teams SharePoint and folder structure, Monitoring corporate deck website updates, Coordinating basic Website updates including redline reviews, Management of meeting minutes into IRI platform, Bachelors degree in communications, public relations or a related field preferred, 3-5 years previous experience in a communications role or related field. JOB DESCRIPTION Nxu is seeking an experienced Director of Investor Relations to manage relationships with our shareholders, analysts, and investors including retail and institutional. Thanks, operator. Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company. The Manager of Investor Relations will be responsible for assisting the Senior Director of Investor Relations with investor relations strategies, managing the quarterly earnings process Equitable - New York Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations & Strategic Finance Ankit Ma Read more From Logan Airport via MBTAComing from Logan Airport, take the Silver Line to South Station, transfer to the Red Line and get off at Central Square. Thanks to all listening for your participation today. Led by an executive team with deep experience and world-class scientific talent, Spero is dedicated to delivering differentiated medicines that help patients suffering from serious and life-threatening infections. WebInvestor Relations Stock information, SEC filings, corporate governance, IR resources and more. We appreciated the opportunity to provide an update on our recent progress, and we look forward to the continued advancement of all of our programs. CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on December 19, 2022, the Compensation Committee of Speros Board of Directors approved a grant of 155,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are subject to the terms and conditions of the 2019 Inducement Plan and an RSU agreement covering the grant. Please go ahead. SPR206 is an IV-administered next generation polymyxin product candidate designed to act directly on Gram-negative bacterial infections through the molecules interactions with the bacterial outer membrane. Spero Therapeutics, Inc. With more online, real-time compensation data than any other website, Salary.com helps you determine your exact pay target. The average hourly wage for an Investor Relations Administrator at companies like SPERO THERAPEUTICS INC in the United States is $50 as of June 26, 2023, but the range typically falls between $42 and $58. The average salary for Investor Relations Manager at companies like SPERO THERAPEUTICS INC in the United States is $153,699 as of June 26, 2023, but the range typically falls between $123,587 and $174,438. Provides input to strategic decisions that affect the functional area of responsibility. Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The total hourly cash compensation, which includes base and short-term incentives, can vary anywhere from $45 to $66 with the average total hourly cash compensation of $55. Although, total revenues for the year-over-year comparisons are the same, grant revenue was approximately $493,000 lower for 2023, while collaboration revenue was $493,000 higher due to recognition of revenue related to the GSK transaction. WebJob Title: Director, Investor Relations . Handles shareholder requests for information. One is just from a numbers perspective. Turning our attention to our remaining financial results. Benefits and Compensation The base salary hiring range for this position is $175,321 - $241,066.*. WebExcitement about the vision and mission of Sage. Maybe on a high level some of the maybe notable differences within this protocol and the one that you used in ADAPT-PO trial? For a Type A Meeting with the FDA conducted last year, positive results from this planned trial together with confirmatory non-clinical evidence of efficacy could be sufficient to support tebipenem HBrs approval. Several factors that could cause or contribute to such differences are described in detail in Spero Therapeutics filings with the SEC, including in the Risk Factors section of our quarterly report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC today. Thank you for participating and have a pleasant day. Typically reports to top management. The webcasts for both events may also be accessed through Spero Therapeutics website (www.sperotherapeutics.com) on the Events and Presentations page under the Connect tab. Spero reported a net loss for the first quarter ended March 31, 2023 of $13.3 million or $0.25 per share of common stock compared to a net loss of $32.8 million or $1.01 per share of common stock reported for the same period in 2022. Learn More Recently Published PASTEUR Act Reintroduced Pipeline Explore Spero's Pipeline * Coordinating logistics for non-deal ZipRecruiter ATS Jobs for ZipSearch/ZipAlerts - 4 days ago, West Valley Staffing Group - Santa Clara Operator? Before we begin, Id like to remind you that some of the information presented on this conference call contains forward-looking statements based on our current expectations, including statements about the future development and commercialization of SPR720, SPR206 and tebipenem HBr, and the design, initiation, timing, progress and results of the companys preclinical studies and clinical trials and its research and development programs, managements assessment of the results of such preclinical studies and clinical trials, the companys cash forecast and anticipated expenses and the sufficiency of its cash resources. CA. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in ph How much does an Investor Relations Manager make at companies like SPERO THERAPEUTICS INC in the United States? Remember that, when we think about patients with NTM, theres two types. Spero Therapeutics to Present at Upcoming Investor Conferences February 28, 2023 08:05 ET | Source: Spero Therapeutics, Inc. Spero Therapeutics, Inc. Ill remind those listening that the planned Phase 2 trial will be funded entirely by external undiluted sources, highlighting the capital efficient approach being employed to advance our pipeline. Stimulating.
Primrose After School Care Cost, Articles S